An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Investigator Site 27 - AT0430001, Vienna

Investigator Site 35 - NL0310001, Amsterdam

Investigator Site 28 - BE0320001, Leuven

Investigator Site 26 - AT0430002, Innsbruck

Investigator Site 33 - DE0490004, Berlin

Investigator Site 20 - FR0330001, Marseille

Investigator Site 18 - ES0340002, Santiago de Compostela

Investigator Site 30 - IT0390004, Genova

Investigator Site 17 - US0010012, Philadelphia

Investigator Site 21 - IT0390002, Milan

Investigator Site 14 - US0010010, Richmond

Investigator Site 34 - DE0490005, Hanover

Investigator Site 16 - US0010009, Augusta

Investigator Site 15 - US0010014, Coral Springs

Investigator Site 9 - 0010006, Boca Raton

Investigator Site 23 - FR0330005, Bordeaux

Investigator Site 31 - IT0390005, Bologna

Investigator Site 36 - DE0490002, Bochum

Investigator Site 32 - DE0490001, Essen

Investigator site 39 - IT0390006, Pisa

Investigator Site 24 - FR0330004, Lille

Investigator Site 6 - US0010008, Meadows

Investigator Site 8 - US0010003, Chicago

Investigator Site 12 - US0010004, Kansas City

Investigator site 38 - FR0330002, Paris

Investigator Site 11 - US0010011, Austin

Investigator Site 10 - US0010007, Carlsbad

Investigator Site 7 - US0010001, Orange

Investigator Site 13 - US0010013, Portland

Investigator Site 29 - CA0019003, London

Investigator site 37 - CA0019002, Québec

Investigator Site 25 - FR0330003, Nice

Investigator Site 2 - GEO9950002, Tbilisi

Investigator Site 1 - GEO9950001, Tbilisi

Investigator Site 3 - GEO9950003, Tbilisi

Investigator Site 22 - IT0390001, Roma

Investigator Site 5 - PL0480002, Krakow

Investigator Site 4 - PL0480001, Lubin

Investigator Site 19 - ES0340001, Barcelona